COMPARATIVE ANALYSIS OF QUANTITATIVE COMPUTED TOMOGRAPHY DATA AND HISTOLOGICAL FINDINGS IN PATIENTS WITH GIANT CELL BONE TUMOR TREATED WITH DENOSUMAB
Background. Giant cell tumor of bone (GCTB) is a common benign lesion accounting for 4–9.5 % of all primary bone tumors. Although surgery is considered the method of choice in the treatment of GCT, however, denosumab, a genetically engineered drug with a novel mechanism of action, has been recently...
Saved in:
| Main Authors: | S. A. Tabakaev, I. G. Frolova, I. I. Anisenya, N. V. Vasilyev, A. V. Bogoutdinova, P. K. Sitnikov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2021-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1751 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
by: DENO Research Group, et al.
Published: (2025-01-01) -
USE OF DENOSUMAB IN GIANT-CELL TUMOR AT A PUBLIC HOSPITAL IN SOUTHERN BRAZIL: REPORT OF 13 CASES
by: Tamise da Silva Baptista, et al.
Published: (2019-01-01) -
Clinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities
by: Zhang S, et al.
Published: (2024-12-01) -
Preoperative denosumab combined with microwave ablation for joint preservation in advanced giant cell tumor of bone: a retrospective study
by: Chuanxi Zheng, et al.
Published: (2025-02-01) -
Denosumab-Induced Osteonecrosis of the Jaw with FDG PET/CT imaging features.
by: SALONI RAJKOTIA, et al.
Published: (2024-11-01)